Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/08/2012WO2012125405A9 Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
11/08/2012WO2012124982A3 Oral preparation having an enteric coating
11/08/2012WO2012124973A3 Combined formulation with improved stability
11/08/2012WO2012122865A3 Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method therefor, and medical use thereof
11/08/2012WO2012119045A3 Compositions and uses thereof to ameliorate pain
11/08/2012WO2012118812A3 Substituted 6,5-fused bicyclic heteroaryl compounds
11/08/2012WO2012114352A3 Pharmaceutical compositions of maraviroc and process for the preparation thereof
11/08/2012WO2012106058A3 Animal treatments
11/08/2012WO2012096859A3 Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
11/08/2012WO2012093859A3 Antifungal composition including polycyclic peptide compound and method for producing same
11/08/2012WO2012093809A3 New bicyclic compound for modulating g protein-coupled receptors
11/08/2012WO2012093404A3 Parenteral formulations of levosimendan
11/08/2012WO2012092569A3 Compositions comprising immunostimulatory nucleic acids and related methods
11/08/2012WO2012092411A3 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
11/08/2012WO2012092409A3 Macrocyclic hepatitis c serine protease inhibitors
11/08/2012WO2012088519A8 Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
11/08/2012WO2012088379A9 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
11/08/2012WO2012083112A3 C- 17 -heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
11/08/2012WO2012080729A4 Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
11/08/2012WO2012078647A3 Chemical composition to detect and treat amyloid in a patient's brain and retina
11/08/2012WO2012075447A4 Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
11/08/2012WO2012074960A3 Fty720-derived anticancer agents
11/08/2012WO2012068381A8 Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
11/08/2012WO2012068096A3 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
11/08/2012WO2012062685A3 Pharmaceutical composition for treating hcv infections
11/08/2012WO2012053003A9 A novel herbal oil for controlling blood sugar without risk of hypoglycemea
11/08/2012WO2011128628A3 Gelled oral pharmaceutical compositions
11/08/2012WO2011114271A8 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspiro [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
11/08/2012WO2011003018A9 Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
11/08/2012WO2006002840A8 Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
11/08/2012US20120283695 Transdermal drug delivery patch and method of controlling drug release of the same by near-ir
11/08/2012US20120283670 Percutaneous absorption preparation comprising anti-dementia drug
11/08/2012US20120283620 Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
11/08/2012US20120283461 Pasteurisation process for microbial cells and microbial oil
11/08/2012US20120283335 Analogs of Propofol, Preparation Thereof and Use as Anesthetics
11/08/2012US20120283334 Treatment of Viral Infections
11/08/2012US20120283332 Transdermal delivery of metformin
11/08/2012US20120283331 Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation
11/08/2012US20120283330 Methods for the treatment of dermatological disorders
11/08/2012US20120283329 S isomers of alpha-methyl hydrocinnamic acid for the treatment of blood disorders
11/08/2012US20120283328 Photosensitizer composition for treating skin disorders
11/08/2012US20120283327 Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina
11/08/2012US20120283326 Anthranilic acid derivatives
11/08/2012US20120283325 Excipient compatibility with ezatiostat
11/08/2012US20120283324 Antagonists and agonists of bitter taste receptors and uses thereof
11/08/2012US20120283323 Treating Learning Deficits with Inhibitors of HMG CoA Reductase
11/08/2012US20120283322 Rhus Verniciflua Stokes Extract Having Increased Content Of Active Flavonoid Compound And Method For Preparing Same
11/08/2012US20120283321 Use of gambierol for treating and/or preventing neurodegenerative diseases related to tau and beta-amyloid
11/08/2012US20120283320 Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
11/08/2012US20120283319 Oligomeric compounds and compositions for use in modulation of small non-coding rnas
11/08/2012US20120283318 Replicating viral vectors for gene therapy
11/08/2012US20120283317 Methods and Compositions for Regulating RNA Import into Mitochondria
11/08/2012US20120283316 Delivery of Therapeutic Agents Using Oligonucleotide-Modified Nanoparticles As Carriers
11/08/2012US20120283315 Sdf-1 delivery for treating ischemic tissue
11/08/2012US20120283314 Sodium channel protein type iii alpha-subunit splice variant
11/08/2012US20120283313 Inhibition and treatment of prostate cancer metastasis
11/08/2012US20120283312 Modulation of eif4e expression
11/08/2012US20120283311 siRNA Targeting Glucagon Receptor (GCCR)
11/08/2012US20120283310 MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
11/08/2012US20120283309 Sirna compounds comprising terminal substitutions
11/08/2012US20120283308 Animal feed composition
11/08/2012US20120283307 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
11/08/2012US20120283306 Mouse model for avm
11/08/2012US20120283305 Cysteine protease inhibitors
11/08/2012US20120283304 Formulations of Temozolomide for Parenteral Administration
11/08/2012US20120283303 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
11/08/2012US20120283302 Scca-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient
11/08/2012US20120283301 S-triazolyl alpha-mercapto acetanilides as inhibitors of hiv reverse transcriptase
11/08/2012US20120283300 Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
11/08/2012US20120283299 Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient
11/08/2012US20120283298 Methods for treating memory impairment
11/08/2012US20120283297 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
11/08/2012US20120283296 Pyrrolopyrazoles for treating cns disorders
11/08/2012US20120283295 Indazole derivatives and their use for blockading voltage dependent sodium channels
11/08/2012US20120283293 Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
11/08/2012US20120283292 Fatty acid lenalidomide and their uses
11/08/2012US20120283291 Solid pharmaceutical composition comprising donepezil hydrochloride
11/08/2012US20120283290 Quantitation of gl3 in urine
11/08/2012US20120283289 Crystalline form of a biphenyl compound
11/08/2012US20120283288 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
11/08/2012US20120283287 Certain chemical entities, compositions, and methods
11/08/2012US20120283286 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
11/08/2012US20120283285 Treatment of solid tumors with rapamycin derivatives
11/08/2012US20120283284 Melonine bisindole compounds, pharmaceutical compositions, preparation method and use thereof
11/08/2012US20120283283 Methods for detecting enhanced risk of opioid-induced hypoxia in a patient
11/08/2012US20120283282 Photoproducts of Tryptophan, Their Synthesis and Uses Thereof
11/08/2012US20120283281 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents
11/08/2012US20120283280 Imidazotetrazinone-based combi-molecules
11/08/2012US20120283279 Combination
11/08/2012US20120283278 Combination
11/08/2012US20120283277 Inhibitors of bruton's tyrosine kinase
11/08/2012US20120283276 Inhibitors of bruton's tyrosine kinase
11/08/2012US20120283275 Methods and dosage forms for reducing side effects of benzisozazole derivatives
11/08/2012US20120283274 Crystalline forms of substituted pyrazolopyrimidines
11/08/2012US20120283273 Indole and azaindole modulators of the alpha 7 nachr
11/08/2012US20120283272 Compounds for inflammation and immune-related uses
11/08/2012US20120283271 Isoindolinone derivatives
11/08/2012US20120283270 Extracts and beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-, (3s,6s)-
11/08/2012US20120283269 Method and Compositions for Suppression of Aging
11/08/2012US20120283268 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers
1 ... 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 ... 7860